TNFRSF9 and neoplasm: CARs were studied that target various tumor antigens such as the B cell maturation antigen (BCMA), CD19, disialoganglioside GD2 (GD2), glypican-3 (GPC3) and epidermal growth factor receptor variant III (EGFRvIII), and contain different costimulatory domains including CD28 and 4-1BB (Fig. 1d and Supplementary Fig. 1a)24–28.